Covid-19 vaccine, with developments that could lead to some Americans getting inoculated in the final days of 2020.Pfizer Inc.
and German partner BioNTech SE this month plan to reveal late-stage results showing whether or not their two-shot regimen is effective in preventing the spread of the virus.“This could be a key catalyst for not only the companies, but the entire market," JPMorgan analyst Cory Kasimov said.Another potential market-moving event comes on Oct.
22. A Food and Drug Administration advisory committee made up of outside experts is likely to review new results and updates on trial enrollments as well as hash out distribution plans.